Pemrametostat succinate
Based on 33 publication(s) in Google Scholar
GSK3326595 succinate (EPZ015938 succinate) is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 succinate decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 succinate can be used for research of relapsed/refractory mantle cell lymphoma.
For research use only. We do not sell to patients.
- CAS No.: 1848944-46-6
- Formula: C28H38N6O7
- Molecular Weight:570.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Pemrametostat succinate
More- Gut. 2024 Sep 11:gutjnl-2024-332998. [Abstract]
- Nat Commun. 2025 Dec 3;16(1):10129. [Abstract]
- Nat Commun. 2021 Jun 8;12(1):3444. [Abstract]
- J Adv Res. 2025 Nov 5:S2090-1232(25)00874-4. [Abstract]
- J Exp Clin Cancer Res. 2022 Oct 5;41(1):293. [Abstract]
- Adv Sci (Weinh). 2025 Sep;12(33):e08280. [Abstract]
- MedComm (2020). 2024 Sep 20;5(10):e705. [Abstract]
- Cell Death Dis. 2026 Feb 2;17(1):195. [Abstract]
- Cancer Lett. 2026 May 1:645:218395. [Abstract]
- Clin Cancer Res. 2025 Jun 24. [Abstract]
- Oncogene. 2021 Apr;40(15):2711-2724. [Abstract]
- EMBO Mol Med. 2023 Aug 7;15(8):e17248. [Abstract]
- Blood Adv. 2022 Apr 28;bloodadvances.2021006306. [Abstract]
- Cell Mol Life Sci. 2023 Jan 17;80(2):43. [Abstract]
- Biomed J. 2026 Jun 10:101002. [Abstract]
- EMBO Rep. 2025 Oct 6. [Abstract]
- Invest Ophthalmol Vis Sci. 2025 Jun 2;66(6):8. [Abstract]
- Transl Oncol. 2025 Feb:52:102264. [Abstract]
- Sci Rep. 2023 Jul 3;13(1):10752. [Abstract]
- Cancers (Basel). 2023 Apr 27;15(9):2501. [Abstract]
- J Cell Mol Med. 2024 Mar;28(5):e17856. [Abstract]
- J Biol Chem. 2022 Oct;298(10):102434. [Abstract]
- Breast Cancer (Dove Med Press). 2023 Nov 6:15:785-799. [Abstract]
- Mol Carcinog. 2023 Aug;62(8):1119-1135. [Abstract]
- Glycobiology. 2024 Dec 10;34(12):cwae081. [Abstract]
- bioRxiv. 2026 Apr 13.
- bioRxiv. 2026 Feb 18:2026.02.16.706212. [Abstract]
- SSRN. 2025 Dec 1.
- Res Sq. 2025 Jul 14.
- bioRxiv. 2024 Aug 16:2024.08.15.608201. [Abstract]
- Medical University of South Carolina. 2023 Aug 12.
- Research Square Print. November 11th, 2022.
- Springer. 2021 May 12.
-
WB
-
Cell Proliferation/Viability Assay
-
WB
-
IHC
-
Cell Proliferation/Viability Assay
All Histone Methyltransferase Isoforms
More
Biological Activity
Description
IC50 & Target
|
PRMT5 |
CDK4 |
CDK6 |
In Vitro
GSK3326595 (10-100 nM, 24-72 h) succinate (EPZ015938 succinate) inhibits SARS-CoV-2spike pseudovirus infection HEK-293 cells and A549 cells by attenuating ACE2-RBD interaction[1].
GSK3326595 (100 nM, 12 h) succinate primes peritoneal macrophages to IFN-gamma-induced M1 polarization[3].
GSK3326595 (0.15-10 μM, 72 h) succinate induces cell death in MCL cell[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK-293T cells, A549 cells
-
Concentration:10 nM, 25 nM, 50 nM, 100 nM
-
Incubation Time:48 h
-
Result:Strongly inhibited ACE2-RBD interaction at low concentration. Inhibited SARS-CoV-2 Omicron and other variants Spike1 binding with ACE2. Inhibits SARS-CoV-2 spike pseudovirus infection host cells.
-
Cell Line:MCL cells
-
Concentration:0.15 μM, 0.3 μM, 0.6 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM
-
Incubation Time:72 h
-
Result:Resulted in modest growth inhibition in MCL cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LDL receptor knockout mice[3]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Did not alter atherosclerosis susceptibility. Increased hepatic triglyceride levels without changing the hyperlipidemia extent. Activated genes involved in fatty acid acquisition.
-
Animal Model:myelocytomatosis transgene turned on mice[5]
-
Dosage:25 mg/kg, 50 mg/kg
-
Administration:Oral
-
Result:Significantly suppressed tumor growth at 50 mg/kg. Showed better therapeutic efficacy at 25 mg/kg.
Chemical Information
-
CAS No. 1848944-46-6
-
Molecular Weight 570.64
-
Formula C28H38N6O7
-
SMILES
OC(CCC(O)=O)=O.O=C(C1=NC=NC(NC2CCN(CC2)C(C)=O)=C1)NC[C@H](O)CN3CC4=CC=CC=C4CC3
-
Synonyms
GSK3326595 succinate; EPZ015938 succinate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (33)
-
Journal Impact Factor
-
Most Recent
-
Gut
2024 Sep 11:gutjnl-2024-332998. PMID: 39266051
Pemrametostat succinate purchased from MedChemExpress. Usage Cited in: Gut. 2024 Sep 11:gutjnl-2024-332998. [Abstract]
GI50 values for the PRMT5 inhibitors GSK3326595 and JNJ64619178 (Onametostat) in the indicated CCA cell lines.
Pemrametostat succinate purchased from MedChemExpress. Usage Cited in: Gut. 2024 Sep 11:gutjnl-2024-332998. [Abstract]
Immunoblot analysis of PRMT5-dependent symmetric dimethylarginine (SMDA) protein marks in control and GSK3326595 or JNJ64619178 (Onametostat) treated HuCCT-1 and TFK-1 cells at the indicated doses for 5 days.
Pemrametostat succinate purchased from MedChemExpress. Usage Cited in: Gut. 2024 Sep 11:gutjnl-2024-332998. [Abstract]
Immunohistochemical analysis of CK19 and H&E stainings showing the extent of CCA lesions in control JnkΔhepa+DEN+CCl4 and GSK3326595-treated mice. Representative images are shown.
-
Nat Commun
2025 Dec 3;16(1):10129. PMID: 41339334 -
Nat Commun
2021 Jun 8;12(1):3444. PMID: 34103528
Pemrametostat succinate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 8;12(1):3444. [Abstract]
Breast cancer cells are treated with DMSO, 0.5 μM GSK3326595 (GSK) for 4 days before examining cell viability.
-
J Adv Res
The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. [Abstract]2025 Nov 5:S2090-1232(25)00874-4. PMID: 41203070 -
J Exp Clin Cancer Res
2022 Oct 5;41(1):293. PMID: 36199122 -
Adv Sci (Weinh)
2025 Sep;12(33):e08280. PMID: 40642900
Pemrametostat succinate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Sep;12(33):e08280. [Abstract]
HCT116 cells were treated with GSK3326595 (10 μM) for 6 h,HCT116 cells were starved in amino acid-free medium for 1 h, and then supplemented with ZnSO4 for the indicated time. The level of pS473-AKT,binding
-
MedComm (2020)
SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumors. [Abstract]2024 Sep 20;5(10):e705. PMID: 39309689 -
Cell Death Dis
Reversible arginine methylation regulates mitochondrial IDH2 activity: coordinated control by CARM1 and KDM3A/4A. [Abstract]2026 Feb 2;17(1):195. PMID: 41629283 -
Cancer Lett
DysUFMylation reprograms immunosuppressive neutrophils to potentiate anti-PD-1 therapy in hepatocellular carcinoma. [Abstract]2026 May 1:645:218395. PMID: 41780840 -
Clin Cancer Res
MTA-Cooperative PRMT5 Inhibitors are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models. [Abstract]2025 Jun 24. PMID: 40553452 -
Oncogene
2021 Apr;40(15):2711-2724. PMID: 33712705 -
EMBO Mol Med
2023 Aug 7;15(8):e17248. PMID: 37458145 -
Blood Adv
Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling. [Abstract]2022 Apr 28;bloodadvances.2021006306. PMID: 35482445 -
Cell Mol Life Sci
Opposing USP19 splice variants in TGF-β signaling and TGF-β-induced epithelial-mesenchymal transition of breast cancer cells. [Abstract]2023 Jan 17;80(2):43. PMID: 36646950 -
Biomed J
2026 Jun 10:101002. PMID: 42270077 -
EMBO Rep
2025 Oct 6. PMID: 41053315 -
Invest Ophthalmol Vis Sci
PRMT5 Regulates Senescence in Retinal Ganglion Cells by Targeting the Wnt/β-Catenin Signaling Cascade. [Abstract]2025 Jun 2;66(6):8. PMID: 40459496 -
Transl Oncol
TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers. [Abstract]2025 Feb:52:102264. PMID: 39756156 -
Sci Rep
2023 Jul 3;13(1):10752. PMID: 37400460 -
Cancers (Basel)
2023 Apr 27;15(9):2501. PMID: 37173967 -
J Cell Mol Med
2024 Mar;28(5):e17856. PMID: 37461162 -
J Biol Chem
Protein arginine methyltransferase 5 is essential for oncogene product EWSR1-ATF1-mediated gene transcription in clear cell sarcoma. [Abstract]2022 Oct;298(10):102434. PMID: 36041632 -
Breast Cancer (Dove Med Press)
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers. [Abstract]2023 Nov 6:15:785-799. PMID: 37954171 -
Mol Carcinog
PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia. [Abstract]2023 Aug;62(8):1119-1135. PMID: 37144835 -
Glycobiology
Compromised CDK12 activity causes dependency on the high activity of O-GlcNAc transferase. [Abstract]2024 Dec 10;34(12):cwae081. PMID: 39361894 -
-
bioRxiv
Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]2026 Feb 18:2026.02.16.706212. PMID: 41757027 -
-
-
bioRxiv
2024 Aug 16:2024.08.15.608201. PMID: 39211199 -
-
-
Purity & Documentation
References
[1]. Che Y, et al. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations [J]. Blood cancer journal, 2023, 13(1): 27. [Content Brief]
[5]. Luo Y, et al. Myelocytomatosis-protein arginine N-methyltransferase 5 Axis defines the tumorigenesis and immune response in hepatocellular carcinoma [J]. Hepatology, 2021, 74(4): 1932-1951. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)